ATE197719T1 - Verwendung von mesothelialen zellen in der gentherapie - Google Patents

Verwendung von mesothelialen zellen in der gentherapie

Info

Publication number
ATE197719T1
ATE197719T1 AT94920753T AT94920753T ATE197719T1 AT E197719 T1 ATE197719 T1 AT E197719T1 AT 94920753 T AT94920753 T AT 94920753T AT 94920753 T AT94920753 T AT 94920753T AT E197719 T1 ATE197719 T1 AT E197719T1
Authority
AT
Austria
Prior art keywords
mesothelial cells
mesothelial
expression system
gene therapy
situ
Prior art date
Application number
AT94920753T
Other languages
English (en)
Inventor
Ty Robert Shockley
Robert William Jackman
Janice Ann Nagy
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Application granted granted Critical
Publication of ATE197719T1 publication Critical patent/ATE197719T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0688—Cells from the lungs or the respiratory tract
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94920753T 1993-06-18 1994-06-15 Verwendung von mesothelialen zellen in der gentherapie ATE197719T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/080,474 US5645829A (en) 1993-06-18 1993-06-18 Mesothelial cell gene therapy
PCT/US1994/006809 WO1995000654A1 (en) 1993-06-18 1994-06-15 Mesothelial cell gene therapy

Publications (1)

Publication Number Publication Date
ATE197719T1 true ATE197719T1 (de) 2000-12-15

Family

ID=22157605

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94920753T ATE197719T1 (de) 1993-06-18 1994-06-15 Verwendung von mesothelialen zellen in der gentherapie

Country Status (9)

Country Link
US (2) US5645829A (de)
EP (2) EP1024197A3 (de)
JP (1) JP3466194B2 (de)
AT (1) ATE197719T1 (de)
AU (1) AU688342B2 (de)
CA (1) CA2164424A1 (de)
DE (1) DE69426328T2 (de)
ES (1) ES2152986T3 (de)
WO (1) WO1995000654A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
EP0781333A1 (de) * 1994-08-26 1997-07-02 Novartis AG (Novartis SA) (Novartis Inc.) Gentherapie für transplantation und entzündliche oderthrombotische zustände
US5704910A (en) * 1995-06-05 1998-01-06 Nephros Therapeutics, Inc. Implantable device and use therefor
DK0970206T3 (da) 1997-01-27 2008-10-13 Ludwig Inst Cancer Res Lage-1-tumorassocierede nukleinsyrer
CA2205076A1 (en) 1997-05-14 1998-11-14 Jim Hu Episomal expression cassettes for gene therapy
US6548296B1 (en) 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
AU735607B2 (en) * 1997-08-13 2001-07-12 Yale University Central nervous system axon regeneration
US20080233098A1 (en) * 1997-10-31 2008-09-25 Mckerracher Lisa RHO Family Antagonists and Their Use to Block Inhibition of Neurite Outgrowth
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
US7169783B2 (en) * 1998-11-02 2007-01-30 Universite De Montreal (+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
DE69939553D1 (de) 1998-12-30 2008-10-23 Beth Israel Hospital Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
US7063959B1 (en) 1998-12-30 2006-06-20 Beth Israel Deaconess Medical Center, Inc. Compositions of the SOC/CRAC calcium channel protein family
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
US6696272B1 (en) 1999-06-02 2004-02-24 Hsc Research & Development Limited Partnership Products and methods for gaucher disease therapy
DK1207905T3 (da) 1999-09-03 2011-01-03 Brigham & Womens Hospital Fremgangsmåder og sammensætninger til behandling af inflammatorisk sygdom under anvendelse af cadherin-II modulerende midler
US20020142299A1 (en) * 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
PT1515752E (pt) 2002-06-19 2009-03-05 Univ Health Network Activação de ace2 para o tratamento de doença cardíaca, pulmonar e renal e de hipertensão
CA2515708A1 (en) 2003-02-11 2004-08-26 Transkaryotic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
US7335496B2 (en) * 2003-06-05 2008-02-26 Ajinomoto Co., Inc. Method for producing target substance
US20060052324A1 (en) * 2004-08-05 2006-03-09 Artandi Steven E Methods and compositions for cell activation
ATE450276T1 (de) * 2004-12-08 2009-12-15 Pervasis Therapeutics Inc Materialien und verfahren zur minimal invasiven abgabe einer zellhaltigen fliessfähigen zusammensetzung
CA2605080A1 (en) * 2005-04-21 2006-11-02 Massachusetts Institute Of Technology Materials and methods for altering an immune response to exogenous and endogenous immunogens, including syngeneic and non-syngeneic cells, tissues or organs
EP2361591A3 (de) * 2005-06-21 2011-12-21 Pervasis Therapeutics, Inc. Verfahren und Zusammensetzungen zur Verbesserung des vaskulären Zugangs
US7977314B2 (en) 2005-12-02 2011-07-12 Amorfix Life Sciences Limited Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
US20100204783A1 (en) * 2005-12-06 2010-08-12 Helen Marie Nugent Methods and compositions for enhancing vascular access
US20090074733A1 (en) * 2005-12-09 2009-03-19 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
US20090068158A1 (en) * 2005-12-09 2009-03-12 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
JP5372764B2 (ja) * 2006-11-07 2013-12-18 シャイア リジェネラティブ メディシン， インコーポレイテッド 血管形成関連疾患の治療および管理のための材料および方法
CA2584494A1 (en) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
WO2009014565A2 (en) 2007-04-26 2009-01-29 Ludwig Institute For Cancer Research, Ltd. Methods for diagnosing and treating astrocytomas
WO2008134879A1 (en) 2007-05-04 2008-11-13 University Health Network Il-12 immunotherapy for cancer
US20100185156A1 (en) * 2007-06-13 2010-07-22 Pervasis Therapeutics, Inc. Methods and Devices for Minimally-Invasive Delivery of Cell-Containing Flowable Compositions
EP2077119A1 (de) * 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Behandlung von Fibrosen und Lebererkrankungen
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
US8568709B2 (en) 2008-03-20 2013-10-29 University Health Network Thymidylate kinase fusions and uses thereof
JP2011515399A (ja) 2008-03-20 2011-05-19 ユニバーシティー オブ マイアミ 熱ショックタンパクｇｐ９６ワクチン接種及びそれを用いた方法
US20100082113A1 (en) * 2008-04-29 2010-04-01 Peter Gingras Tissue repair implant
AU2009327485A1 (en) 2008-06-18 2010-06-24 Cytopherx, Inc. Methods for propagation of renal precursor cells
EP2515930A4 (de) 2009-12-21 2013-04-10 Tty Biopharm Co Ltd Verfahren und zusammensetzungen im zusammenhang mit reduzierter met-phosphorylierung durch aus leukozyten gewonnenes chemotaxin 2 in tumorzellen
KR20190000385A (ko) 2010-05-04 2019-01-02 더 브리검 앤드 우먼즈 하스피털, 인크. 섬유증의 검출 및 치료
WO2017039751A1 (en) 2015-08-28 2017-03-09 Bioincept, Llc Mutant peptides and methods of treating subjects using the same
WO2014074785A1 (en) 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Methods of predicting outcome and treating breast cancer
CA2891510C (en) 2012-11-16 2022-10-18 Transposagen Biopharmaceuticals, Inc. Site-specific enzymes and methods of use
EP3060924B1 (de) * 2013-10-22 2022-06-01 Bioincept LLC Pif-transfizierte zellen und verfahren zur verwendung
RU2553342C1 (ru) * 2014-04-18 2015-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава России) Способ лечения инфекционного перитонита в эксперименте
US11473082B2 (en) 2015-06-17 2022-10-18 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
EP3341006A4 (de) 2015-08-28 2019-03-13 BioIncept LLC Zusammensetzungen und verfahren zur behandlung von nervenschäden
WO2019126578A1 (en) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755593A (en) * 1985-07-24 1988-07-05 Lauren Mark D Novel biomaterial of cross-linked peritoneal tissue
US5443954A (en) * 1987-10-30 1995-08-22 The United States Of America As Represented By The Department Of Health And Human Services Immortalized non-tumorigenic human bronchial epithelial cell lines
US4885238A (en) * 1987-10-30 1989-12-05 The United States Of America As Represented By The Department Of Health And Human Services Immortalized human bronchial epitherial mesothelial cell lines
EP0456640A1 (de) * 1988-12-13 1991-11-21 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Genetisch erzeugte endothelzellen und deren verwendung
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP0452457B1 (de) * 1989-11-03 1997-08-20 Vanderbilt University Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
DE4011100A1 (de) * 1990-01-18 1991-10-10 Jakob Dr Bodziony Ein extrakorporales oder ein implantierbares bio-artifizielles organ, welches verschiedene organfunktionen ersetzen oder unterstuetzen kann
DE4001319A1 (de) * 1990-01-18 1991-07-25 Jakob Dr Bodziony Ein implantierbares und biologisch aktive substanzen sezernierendes bioartifizielles organ
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
IE20010427A1 (en) * 1990-04-10 2003-03-05 Canji Inc Gene therapy for cell proliferative diseases
DE4123629A1 (de) * 1990-08-06 1992-02-20 Jakob Dr Bodziony Ein implantierbares und biologisch aktive substanzen sezernierendes bio-artifizielles organ, das auf dem prinzip des druckgradients funktioniert
CA2091346C (en) * 1990-09-14 2007-04-24 Philip Frost Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
CA2092323A1 (en) * 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
CA2098848A1 (en) * 1990-12-20 1992-06-21 Joseph C. Glorioso Truncated interleukin-1 receptor gene for the treatment of arthritis
WO1992015676A1 (en) * 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Somatic cell gene therapy
DE69233013T2 (de) * 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents

Also Published As

Publication number Publication date
WO1995000654A1 (en) 1995-01-05
EP0703988A1 (de) 1996-04-03
JP3466194B2 (ja) 2003-11-10
EP0703988B1 (de) 2000-11-22
EP1024197A2 (de) 2000-08-02
US6068837A (en) 2000-05-30
EP1024197A3 (de) 2005-11-23
US5645829A (en) 1997-07-08
ES2152986T3 (es) 2001-02-16
DE69426328D1 (de) 2000-12-28
AU7174194A (en) 1995-01-17
CA2164424A1 (en) 1995-01-05
AU688342B2 (en) 1998-03-12
JPH09501048A (ja) 1997-02-04
DE69426328T2 (de) 2002-05-29

Similar Documents

Publication Publication Date Title
DE69426328D1 (de) Verwendung von mesothelialen zellen in der gentherapie
ATE142506T1 (de) Verabreichung von antisensen oligonukleotiden und peptiden als arzeneimittel an geweben in vivo und an zellen durch verwendung von avidin-biotin- technologie
ES2230502T3 (es) Disolucion tampon para la electroporacion y procedimiento que incluye el uso de la misma.
EP0939590A4 (de) Verabreichung therapeutischer genprodukte durch intestinale zell-expression
CY1119369T1 (el) Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της αλφα-γαλακτοσιδασης α
FI955552A0 (fi) Adenoviraalisia eläinperäisiä vektoreita ja niiden käyttö geeniterapiassa
DK0644929T3 (da) System og fremgangsmåde til transplantation af celler
NZ505011A (en) Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
BR0010648A (pt) Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril
ATE370749T1 (de) Zusammensetzungen von nucleinsäure und viskosität-erhöhendem polymer pvp, zur verwendung in gentherapie
FI914427A0 (fi) Expression av exogena polynukleotid- sekvenser i ett ryggradsdjur.
ATE157012T1 (de) Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
DK0661987T3 (da) Morphogeninduceret leverregeneration
DE69830251D1 (de) Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen
BR9806866A (pt) Cassete de expressão e uso do mesmo, cepa do cassete de expressão, vetor de ácido nucleico, cepa viral, composição farmacêutica, e, processos para estudar a função de um ou mais genes heterólogos em uma célula eucariótica, para produzir uma cepa de hsv, para tratamento do corpo humano ou animal e para realizar terapia genética em um humano ou animal, e, vacina.
FR2730411B1 (fr) Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
DE69909041D1 (de) Verwendung von Magnesium (Mg2+) zur Erhöhung der Gen-Verabreichung bei Gentherapie
MX9700560A (es) Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales.
ATE286127T1 (de) Verabreichung der therapeutischen proteine durch implantation der genetischen modifizierten zellen in das omentum
FR2622445B1 (fr) Application de groupes nitrophenyles a la stimulation des capacites d'incorporation d'un medicament dans les cellules sensibles de l'hote
IL148826A (en) Genetically modified mammalian cells and use thereof for the pulmonary system

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties